Janney Montgomery Scott LLC Trims Stock Position in GSK plc (NYSE:GSK)

Janney Montgomery Scott LLC trimmed its position in GSK plc (NYSE:GSK) by 5.2% in the 3rd quarter, Holdings Channel reports. The firm owned 294,806 shares of the pharmaceutical company’s stock after selling 16,256 shares during the quarter. Janney Montgomery Scott LLC’s holdings in GSK were worth $12,052,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its position in GSK by 43.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 13,546 shares of the pharmaceutical company’s stock worth $581,000 after buying an additional 4,126 shares in the last quarter. Rehmann Capital Advisory Group bought a new position in shares of GSK in the first quarter worth approximately $212,000. Csenge Advisory Group raised its stake in GSK by 20.6% in the first quarter. Csenge Advisory Group now owns 19,127 shares of the pharmaceutical company’s stock valued at $820,000 after purchasing an additional 3,271 shares in the last quarter. Advisory Services Network LLC lifted its position in GSK by 28.3% during the first quarter. Advisory Services Network LLC now owns 87,529 shares of the pharmaceutical company’s stock valued at $3,752,000 after purchasing an additional 19,320 shares during the last quarter. Finally, CFO4Life Group LLC purchased a new position in GSK in the 1st quarter worth approximately $235,000. 15.74% of the stock is owned by institutional investors.

GSK Trading Down 3.0 %

NYSE GSK opened at $35.90 on Thursday. The firm has a market cap of $74.39 billion, a PE ratio of 23.31, a price-to-earnings-growth ratio of 1.42 and a beta of 0.66. GSK plc has a 1-year low of $33.89 and a 1-year high of $45.92. The stock has a 50-day moving average of $40.25 and a 200-day moving average of $40.97. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.38%. The ex-dividend date is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 100.00%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research analyst reports. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $50.00.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.00% of the company’s stock.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.